WO2008043829A3 - Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine - Google Patents

Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine Download PDF

Info

Publication number
WO2008043829A3
WO2008043829A3 PCT/EP2007/060871 EP2007060871W WO2008043829A3 WO 2008043829 A3 WO2008043829 A3 WO 2008043829A3 EP 2007060871 W EP2007060871 W EP 2007060871W WO 2008043829 A3 WO2008043829 A3 WO 2008043829A3
Authority
WO
WIPO (PCT)
Prior art keywords
emtricitabine
tenofovir
nevirapine
infection
treating hiv
Prior art date
Application number
PCT/EP2007/060871
Other languages
French (fr)
Other versions
WO2008043829A2 (en
Inventor
Vicente Soriano
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Vicente Soriano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Vicente Soriano filed Critical Boehringer Ingelheim Int
Publication of WO2008043829A2 publication Critical patent/WO2008043829A2/en
Publication of WO2008043829A3 publication Critical patent/WO2008043829A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provides a method for treating HIV wherein emtricitabine, tenofovir and nevirapine are administered once per day.
PCT/EP2007/060871 2006-10-14 2007-10-12 Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine WO2008043829A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82952906P 2006-10-14 2006-10-14
US60/829,529 2006-10-14

Publications (2)

Publication Number Publication Date
WO2008043829A2 WO2008043829A2 (en) 2008-04-17
WO2008043829A3 true WO2008043829A3 (en) 2008-06-26

Family

ID=39251852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/060871 WO2008043829A2 (en) 2006-10-14 2007-10-12 Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine

Country Status (1)

Country Link
WO (1) WO2008043829A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714045A1 (en) 2011-05-30 2014-04-09 Cipla Limited Pharmaceutical antiretroviral composition
JP2015534973A (en) 2012-10-23 2015-12-07 シプラ・リミテッド Antiretroviral pharmaceutical composition
PE20181207A1 (en) 2015-11-09 2018-07-23 Gilead Sciences Inc THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
ES2902136T3 (en) * 2016-02-12 2022-03-25 Cipla Ltd Pharmaceutical compositions comprising an antiretroviral drug and a pharmacokinetic enhancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHI ET AL: "Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9600, 15 November 2007 (2007-11-15), pages 1698 - 1705, XP022346237, ISSN: 0140-6736 *
FOR THE 2NN STUDY TEAM VAN LETH F ET AL: "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 363, no. 9417, 17 April 2004 (2004-04-17), pages 1253 - 1263, XP004763918, ISSN: 0140-6736 *
GARCÍA F ET AL: "Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.", AIDS (LONDON, ENGLAND) 10 NOV 2000, vol. 14, no. 16, 10 November 2000 (2000-11-10), pages 2485 - 2494, XP002476371, ISSN: 0269-9370 *
J.G. BARTLETT: "Antiretroviral therapy", US DEPART.., pages 29 - 38, XP002476367, Retrieved from the Internet <URL:ftp://ftp.hrsa.gov/hab/PCGchap5.pdf> *
MAGGIOLO FRANCO ET AL: "Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.", THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY MAR 2007, vol. 59, no. 3, March 2007 (2007-03-01), pages 569 - 572, XP002476370, ISSN: 0305-7453 *
PIACENTI FRANK J: "An update and review of antiretroviral therapy", PHARMACOTHERAPY, BOSTON, US, vol. 26, no. 8, August 2006 (2006-08-01), pages 1111 - 1133, XP009098604, ISSN: 0277-0008 *
SUSA COFFEY: "Options for Once-Daily Dosing of Antiretrovirals", INTERNET ARTICLE, XP002476369, Retrieved from the Internet <URL:http://www.aids-ed.org/aidsetc?page=et-03-00-01> *
VEMURI SREEVANI ET AL: "Truvada intolerance.", AIDS (LONDON, ENGLAND) 30 JAN 2007, vol. 21, no. 3, 30 January 2007 (2007-01-30), pages 382 - 383, XP002476368, ISSN: 0269-9370 *

Also Published As

Publication number Publication date
WO2008043829A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
WO2007130491A3 (en) Patient customized therapeutic regimens
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
TW200745100A (en) Use of a sulfonamide compound for improving the pharmacokinetics of a drug
WO2006040076A3 (en) Vaccination adjuvants pam3cys, poly(i:c), imiquimod, loxoribine, r-848 and cpg-dna together with mhc i or mhc ii epitopes
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2009025926A3 (en) Nanoparticle-coated medical devices and formulations for treating vascular disease
WO2012174158A3 (en) Administration of benzodiazepine
WO2007144169A3 (en) Entacapone-derivatives
WO2012039596A3 (en) Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2009027849A3 (en) Guava extract
WO2008152115A3 (en) Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
BRPI0920605A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and method for the treatment or prophylaxis of HIV infection or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a patient in need thereof.
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2012158030A3 (en) Drug delivery system
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EP4023659A4 (en) Compound and drug conjugate, and preparation method and use thereof
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
WO2008043829A3 (en) Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
WO2009021971A3 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2009026257A8 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2008033500A3 (en) Carbohydrate-based vaccines for hiv
WO2007144080A3 (en) Combination antidepressants wafer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07821238

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07821238

Country of ref document: EP

Kind code of ref document: A2